Literature DB >> 34763024

Residual effects of busulfan and irradiation on murine hematopoietic stem and progenitor cells.

Kaylind Batey1, Jisoo Kim1, Lauren Brinster2, Gladys Gonzalez-Matias1, Zhijie Wu1, Sabrina Solorzano3, Jichun Chen1, Xingmin Feng4, Neal S Young1.   

Abstract

Exposure of young C57BL/6 (B6) mice to two courses of busulfan (BSF) injections or two rounds of sublethal total-body irradiation (TBI) induced significant damage to the function of hematopoietic stem and progenitor cells (HSPCs). Fifteen weeks after treatment, BSF- and TBI-treated mice had reduced white blood cells without significant change in red blood cells or platelets, indicating that BSF and TBI hematotoxicity was chronic, with leukocytes being the major targets. Hematopoietic damage induced by BSF or TBI persisted long term. Residual adverse effects were reflected by significantly decreased CD45R B cells and reduced recovery of total bone marrow cells, especially HSPCs carrying markers for KSL (Kit+Sca-1+Lin-) cells, multipotent progenitor (MPP) cells (KSLCD34+CD135+), myeloid progenitor (MP) cells (Kit+Sca-1-Lin-), and common lymphoid progenitor (CLP) cells 62 wk posttreatment. Transplantation of bone marrow (BM) cells from BSF and TBI donors at 49 weeks after treatment into lethally irradiated hosts resulted in decreased engraftment of CD45R B cells in blood and reduced reconstitution of BM HSPCs including KSL cells, short-term hematopoietic stem cells (KSLCD34+CD135-), MPP cells, and MP cell subsets. TBI donor had better reconstitution of CLP cells in recipients posttransplantation than did BSF donor, suggesting an impact of TBI and BSF on B cells at different development stages. In summary, BSF and TBI exposure produced long-lasting adverse effects on hematopoiesis with pronounced effects on mature B cells, immature ST-HSCs, and hematopoietic progenitor cells. Our results may have implications for therapy of human diseases. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34763024      PMCID: PMC8724411          DOI: 10.1016/j.exphem.2021.11.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  44 in total

1.  OBSERVATIONS ON SUPRALETHAL WHOLE-BODY IRRADIATION AND MARROW TRANSPLANTATION IN MAN AND DOG.

Authors:  E D THOMAS
Journal:  Ann N Y Acad Sci       Date:  1964-03-31       Impact factor: 5.691

2.  Homografts of bone marrow in dogs after lethal total-body radiation.

Authors:  E D THOMAS; C A ASHLEY; H L LOCHTE; A JARETZKI; O D SAHLER; J W FERREBEE
Journal:  Blood       Date:  1959-06       Impact factor: 22.113

3.  The use of myleran in the treatment of chronic myelocytic leukemia.

Authors:  A HAUT; S J ALTMAN; G E CARTWRIGHT; M M WINTROBE
Journal:  AMA Arch Intern Med       Date:  1955-10

4.  Total body irradiation selectively induces murine hematopoietic stem cell senescence.

Authors:  Yong Wang; Bradley A Schulte; Amanda C LaRue; Makio Ogawa; Daohong Zhou
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

5.  A primary stem cell lesion in experimental chronic hypoplastic marrow failure.

Authors:  A Morley; K Trainor; J Blake
Journal:  Blood       Date:  1975-05       Impact factor: 22.113

6.  Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study.

Authors:  Yazid Belkacemi; Myriam Labopin; Sebastian Giebel; Gokoulakrichenane Loganadane; Leszek Miszczyk; Mauricette Michallet; Gérard Socié; Nicolaas P M Schaap; Jan J Cornelissen; Ibrahim Yakoub-Agha; Emmanuelle Polge; Mohamad Mohty; Norbert Claude Gorin; Arnon Nagler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-19       Impact factor: 7.038

7.  Immune-mediated bone marrow failure in C57BL/6 mice.

Authors:  Jichun Chen; Marie J Desierto; Xingmin Feng; Angélique Biancotto; Neal S Young
Journal:  Exp Hematol       Date:  2014-12-30       Impact factor: 3.084

8.  Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.

Authors:  X Cahu; M Labopin; S Giebel; M Aljurf; S Kyrcz-Krzemien; G Socié; M Eder; F Bonifazi; D Bunjes; S Vigouroux; M Michallet; M Stelljes; T Zuckerman; J Finke; J Passweg; I Yakoub-Agha; D Niederwieser; G Sucak; H Sengeløv; E Polge; A Nagler; J Esteve; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-11-30       Impact factor: 5.483

9.  Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Matthew Whayman; John A Turton
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

10.  Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.

Authors:  Mark Parta; Nirali N Shah; Kristin Baird; Hind Rafei; Katherine R Calvo; Thomas Hughes; Kristen Cole; Meg Kenyon; Bazetta Blacklock Schuver; Jennifer Cuellar-Rodriguez; Christa S Zerbe; Steven M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.